NCT00056875

Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

Safety and Efficacy of Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 50 (planned)
• Sponsor: University of Michigan · Academic / Other
• Sex: All
• Age: 3 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm dose escalation study of recombinant human keratinocyte growth factor given to patients undergoing allogeneic bone marrow transplantation who are at high risk for graft versus host disease (GVHD).

Detailed description

Completion date provided represents the completion date of the grant per OOPD records

Conditions

• Graft Versus Host Disease

Interventions

Type	Name	Description
DRUG	recombinant human keratinocyte growth factor

Timeline

• Start date: 2002-09-01
• Completion: 2005-06-01
• First posted: 2003-03-27
• Last updated: 2015-03-25

Locations

1 site across 1 country: United States